Last updated on Wednesday, 12 August 2020

Christus St Vincent Regional Cancer Center

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-03Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Alliance A011401SupportiveOpen Active2016-09-29Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Lovelace Medical Center-Saint Joseph Square

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-19Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006Breast AdjuvantOpen Active2020-03-27SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
SWOG S1706Breast NeoadjuvantOpen Active2019-06-24SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Alliance A071701Brain AdvancedOpen Active2020-05-21Alliance A071701: Genomically-Guided Treatment Trial in Brain Metastases
SWOG S0820GI Colorectal PreventionOpen Active2018-07-27SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-04-05Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Alliance A021502GI Colorectal AdjuvantOpen Active2018-10-12Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
ECOG-ACRIN EA2165GI OtherOpen Active2019-04-15ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
SWOG S1815GI OtherOpen Active2020-06-22SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-12Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-09SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
INST 96144Ill DefinedOpen Active2015-07-28INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C1Solid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-Z1CSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
Alliance A011401SupportiveOpen Active2016-09-17Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********

Lovelace Radiation Oncology

Trial #TypeStudy StatusStatus DateTitle
NSABP B-51Breast AdjuvantOpen Active2017-04-13NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
Alliance A221505Breast AdvancedOpen Active2018-04-10Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
CCTG MA.39Breast NeoadjuvantOpen Active2018-10-10CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S1706Breast NeoadjuvantOpen Active2019-06-24SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
INST LWH 1806Breast OtherOpen Active2019-03-14INST LWH 1806: TARGIT New Mexico
ECOG-ACRIN EA2165GI OtherOpen Active2019-04-15ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-02-21NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
GOG 0263GYN Cervical AdjuvantOpen Active2017-06-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2017-06-07RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
WFU WF-1801SupportiveOpen Active2019-04-01Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Lovelace Respiratory Research Institute

Trial #TypeStudy StatusStatus DateTitle
LRRI #1054101Lung AncillaryOpen Active2001-03-01LRRI #1054101: Defining Lung Cancer Risk in Current and Former Cigarette Smokers: Risk Factors for Epigenetic Silencing of Lung Cancer Genes

Lovelace Women's Hospital

Trial #TypeStudy StatusStatus DateTitle
Alliance A011202Breast AdjuvantOpen Active2020-05-27Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-04-05Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
INST LWH 1806Breast OtherOpen Active2019-03-14INST LWH 1806: TARGIT New Mexico
INST UNM CR1801Multiple SitesOpen Active2018-09-04INST UNM CR1801: Assessment of Intraoperative Radiofrequency Spectroscopy For Improving Lumpectomy Outcomes with Respect to Re-excision Rates and Lumpectomy Size
Alliance A011401SupportiveOpen Active2017-11-08Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Memorial Medical Center

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-04Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2017-01-26NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1418/BR006Breast AdjuvantOpen Active2020-03-27SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
INST University of Arizona 1807Breast AdvancedOpen Active2020-02-17INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
NRG Oncology NRG-BR004Breast AdvancedOpen Active2019-09-24NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
CCTG MA.39Breast NeoadjuvantOpen Active2018-08-21CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
EA1181Breast NeoadjuvantOpen Active2020-05-14EA1181 -The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-03-27Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
SWOG S1703Breast OtherOpen Active2020-04-28SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
NRG-GI005GI OtherOpen Active2020-06-03NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
SWOG S1815GI OtherOpen Active2020-06-22SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Pharm 010-00GU Prostate AdvancedOpen Active2020-03-04Merck 010-00: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) PlusOlaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
GOG 0263GYN Cervical AdjuvantOpen Active2011-02-07GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
NRG Oncology NRG-GY005GYN OtherOpen Active2019-06-24NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
ECOG-ACRIN NHLBI-MDSHematology OtherOpen Active2020-05-18ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
UNM 1709Ill DefinedOpen Active2019-07-02INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-26SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1800ALung NSCLC AdvancedOpen Active2020-04-08SWOG S1800A: A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
SWOG S1900CLung NSCLC AdvancedOpen Active2020-05-05SWOG S1900C: A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub-Study)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C1Solid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1CSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
Alliance A011401SupportiveOpen Active2016-12-16Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
DCP-001SupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001ASupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001DSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
ECOG-ACRIN E1Q11SupportiveOpen Active2018-04-18ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship

New Mexico Oncology Hematology Consultants

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-04Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2016-10-20NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1418/BR006Breast AdjuvantOpen Active2020-03-27SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance A221505Breast AdvancedOpen Active2018-04-10Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
NRG Oncology NRG-BR004Breast AdvancedOpen Active2019-12-18NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
CCTG MA.39Breast NeoadjuvantOpen Active2018-11-05CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S0820GI Colorectal PreventionOpen Active2018-09-14SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
SWOG S1815GI OtherOpen Active2020-06-22SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Pharm PrTK03GU Prostate AdjuvantOpen Active2017-06-28Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-01-29NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
NRG Oncology NRG-HN004Head And Neck AdvancedOpen Active2019-03-20NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
RTOG 1216Head And Neck AdvancedOpen Active2020-07-24RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Pharm INCB 18424-MA-GD-301Hematology Stem Cell TransplantOpen Active2019-01-29Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
INST 96144Ill DefinedOpen Active2014-12-09INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
UNM 1709Ill DefinedOpen Active2019-07-02INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-17Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-17SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1800ALung NSCLC AdvancedOpen Active2020-04-08SWOG S1800A: A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2020-08-07ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
SWOG S1801Skin Melanoma AdvancedOpen Active2020-05-06SWOG S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable State III-IV High Risk Melanoma
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C1Solid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1CSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations

NMOHC Gallup

Trial #TypeStudy StatusStatus DateTitle
INST 96144Ill DefinedOpen Active2018-06-18INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives

Presbyterian Medical Group

Trial #TypeStudy StatusStatus DateTitle
Alliance A011202Breast AdjuvantOpen Active2020-05-27Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Alliance A011502Breast AdjuvantOpen Active2017-05-08Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006Breast AdjuvantOpen Active2020-03-27SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
NRG Oncology NRG-BR004Breast AdvancedOpen Active2019-09-24NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
SWOG S1703Breast OtherOpen Active2020-03-02SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Alliance A021502GI Colorectal AdjuvantOpen Active2020-01-14Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S0820GI Colorectal PreventionOpen Active2017-11-29SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
SWOG S1815GI OtherOpen Active2020-06-22SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Pharm CA209901GU OtherOpen Active2019-06-11Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
INST 96144Ill DefinedOpen Active2013-06-04INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-26SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1800ALung NSCLC AdvancedOpen Active2020-04-08SWOG S1800A: A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2020-08-07ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C1Solid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1CSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
Alliance A011401SupportiveOpen Active2016-11-01Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Presbyterian Rust Medical Center

Trial #TypeStudy StatusStatus DateTitle
Alliance A011202Breast AdjuvantOpen Active2020-05-27Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Alliance A011502Breast AdjuvantOpen Active2018-04-19Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006Breast AdjuvantOpen Active2020-03-27SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
NRG Oncology NRG-BR004Breast AdvancedOpen Active2019-09-24NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
SWOG S1703Breast OtherOpen Active2020-03-02SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Alliance A021502GI Colorectal AdjuvantOpen Active2020-01-14Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S0820GI Colorectal PreventionOpen Active2018-09-14SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
SWOG S1815GI OtherOpen Active2020-06-22SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
GOG 0263GYN Cervical AdjuvantOpen Active2018-06-07GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
INST 96144Ill DefinedOpen Active2018-04-10INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-08-04Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-05SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1800ALung NSCLC AdvancedOpen Active2020-04-08SWOG S1800A: A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2020-08-07ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
Alliance A011401SupportiveOpen Active2018-04-19Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Southwest Gynecologic Oncology Associates

Trial #TypeStudy StatusStatus DateTitle
GOG 0263GYN Cervical AdjuvantOpen Active2010-12-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-10-30RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Pharm C-750-01/GOG-3028GYN Cervical AdvancedOpen Active2020-02-13Agenus C-750-01/GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (antiPD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
NRG Oncology NRG-GY005GYN OtherOpen Active2019-11-06NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
GOG-3026GYN Ovarian AdvancedOpen Active2020-03-27GOG-3026: A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C1Solid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1CSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********

UNM - CRTC

Trial #TypeStudy StatusStatus DateTitle
Pharm LNS-101Advanced Solid TumorsOpen Active2019-10-11Linnaeus Therapeutics LNS-101: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer
Alliance A071701Brain AdvancedOpen Active2020-04-17Alliance A071701: Genomically-Guided Treatment Trial in Brain Metastases
Alliance A071801Brain AdvancedOpen Active2020-06-11Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
NCCTG N0577Brain AdvancedOpen Active2017-12-18NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
NRG Oncology NRG-BN003Brain OtherOpen Active2017-10-20NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Alliance A011202Breast AdjuvantOpen Active2020-05-27Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Alliance A011502Breast AdjuvantOpen Active2017-05-03Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2016-08-01NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1418/BR006Breast AdjuvantOpen Active2020-03-27SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance A221505Breast AdvancedOpen Active2018-04-10Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-03-28Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
INST University of Arizona 1807Breast AdvancedOpen Active2019-10-24INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
NRG Oncology NRG-BR004Breast AdvancedOpen Active2019-09-24NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Novartis CBYL719X2402Breast AdvancedOpen Active2020-05-19Novartis CBYL719X2402: A Phase II, Multicenter, Open-label, Two-cohort, Noncomparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients with PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), who have Progressed on or after CDK 4/6 Inhibitor Treatment
Pharm RAD1901-308Breast AdvancedOpen Active2019-12-06Radius Pharmaceuticals RAD1901-308: Elacestrant Monotherapy for the Treatment of ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial
Pharm SGNLVA-001Breast AdvancedOpen Active2017-09-26Seattle Genetics, Inc. SGNLVA-001: A Phase I, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of SGN-LIVIA in Patients with LIV-1-Positive Metastatic Breast Cancer
Pharm SGNLVA-002Breast AdvancedOpen Active2018-02-20Seattle Genetics SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
EA1181Breast NeoadjuvantOpen Active2020-05-14EA1181 -The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
CCTG MA.39Breast NeoadjuvantOpen Active2018-09-05CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S1706Breast NeoadjuvantOpen Active2019-06-24SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Alliance Foundation Trials AFT-25Breast OtherOpen Active2018-02-07Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
UNM 1607Breast NeoadjuvantOpen Active2018-04-16INST UNM 1607: Monitoring response to neoadjuvant chemotherapy (NAC) in Early Stage Breast Cancer (ESBC) Using High-speed MR Spectroscopic Imaging (MRSI)
ECOG-ACRIN EA1151Breast OtherOpen Active2018-08-31ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST)
Alliance A231701CDCCDROpen Active2020-07-10Alliance A231701CD: Increasing Socioeconomically Disadvantaged Patients' Engagement in Breast Cancer Surgery Decision Making through a Shared Decision Making Intervention
SWOG S1703Breast OtherOpen Active2020-03-02SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
INST 1311EpidemiologicalOpen Active2017-06-20INST 1311: A Prospective Birth Cohort Study Involving Environmental Uranium Exposure in the Navajo Nation
CIBMTR Protocol for a Research DatabaseEpidemiologicalOpen Active2017-06-29CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
UNM 1803EpidemiologicalOpen Active2018-06-26INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative
Alliance A021502GI Colorectal AdjuvantOpen Active2018-10-12Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
UNM TCCPEpidemiologicalOpen Active2017-12-08INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
INST UNM 1809GI Colorectal PreventionOpen Active2018-12-27INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States
Alliance A021703GI Colorectal AdvancedOpen Active2020-03-03Alliance A021703: Randomized Double-blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
SWOG S0820GI Colorectal PreventionOpen Active2017-10-05SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Pharm 937-00GI Hepatic AdjuvantOpen Active2020-02-04Merck 937-00: A Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
PHARM CP-MGAH22-06GI Gastric AdvancedOpen Active2020-03-13MacroGenics CP-MGAH22-06: A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-nave, HER2-Positive Gastric or Gastroesophageal Junction Cancer
Alliance A021602GI OtherOpen Active2019-05-08Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
INST Dana-Farber Cancer Institute 18-128GI OtherOpen Active2019-07-15INST Dana-Farber Cancer Institute 18-128: EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options - RCT of Usual Chemotherapy Educational Tools versus Investigational Chemotherapy Educational Tools
ECOG-ACRIN EA2165GI OtherOpen Active2019-04-08ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
SWOG S1815GI OtherOpen Active2020-06-22SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
NRG-GI005GI OtherOpen Active2020-06-03NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
UNM 1603GI OtherOpen Active2016-11-30INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health
SWOG S1820GI OtherOpen Active2020-08-05SWOG S1820: A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
Pharm FGCL-3019-087GI Pancreatic AdvancedOpen Active2020-07-16FibroGen FGCL-3019-087: A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer
Pharm 905-00GU OtherOpen Active2020-02-04Merck 905-00: A Phase 3 Randomized Study of Cystectomy plus Peri-operative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Patients with Muscle-invasive Bladder Cancer (KEYNOTE-905)
Pharm 866-00GU OtherOpen Active2019-11-04Merck 866-00: A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
UNM 1805GU OtherOpen Active2019-01-08INST UNM 1805: Trait Mindfulness in Distressed New Mexico Prostate Cancer Survivors
Pharm CA209901GU OtherOpen Active2019-06-11Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Pharm PrTK03GU Prostate AdjuvantOpen Active2017-06-28Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-01-29NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance A031704GU Renal Cell AdvancedOpen Active2019-11-26Alliance A031704: PD-inhibitor (nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: a phase III trial in metastatic untreated REnal cell cancEr (PDIGREE)
Pharm 010-00GU Prostate AdvancedOpen Active2020-02-10Merck 010-00: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) PlusOlaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-07-23RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263GYN Cervical AdjuvantOpen Active2010-10-20GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Pharm C-750-01/GOG-3028GYN Cervical AdvancedOpen Active2019-11-14Agenus C-750-01/GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (antiPD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
NRG Oncology NRG-GY006GYN Cervical AdvancedOpen Active2020-02-18NRG Oncology NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
NCICOVIDGYN OtherOpen Active2020-07-14NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
UNM 1509GYN OtherOpen Active2020-06-29INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
NRG Oncology NRG-GY005GYN OtherOpen Active2019-06-24NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
VBL Therapeutics VB-111-701/GOG 3018GYN Ovarian AdvancedOpen Active2019-08-29VBL Therapeutics VB-111-701/GOG 3018: The OVAL Study: A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
NRG-GY021GYN Ovarian AdvancedOpen Active2020-01-28NRG-GY021: A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
GOG-3026GYN Ovarian AdvancedOpen Active2020-03-27GOG-3026: A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Alliance A041501Hematology Acute LeukemiaOpen Active2020-04-03Alliance A041501: A PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN (A CONJUGATED ANTI-CD22 MONOCLONAL ANTIBODY) TO FRONTLINE THERAPY IN YOUNG ADULTS (AGES 18-39 YEARS) WITH NEWLY DIAGNOSED PRECURSOR B-CELL ALL
RTOG 1216Head And Neck AdvancedOpen Active2020-07-24RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
NRG Oncology NRG-HN004Head And Neck AdvancedOpen Active2019-03-20NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
INST 1310Head And Neck AdvancedOpen Active2015-02-25INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
ECOG-ACRIN EA3161Head And Neck AdvancedOpen Active2020-02-06ECOG-ACRIN EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
ECOG-ACRIN E4412Hematology Lymphoma HodgkinsOpen Active2020-03-13ECOG-ACRIN E4412: A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
SWOG S1712Hematology Chronic LeukemiaOpen Active2019-02-21SWOG S1712: A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease
Alliance A041702Hematology Chronic LeukemiaOpen Active2020-08-07Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
UNM 1512Hematology Acute LeukemiaOpen Active2018-05-23INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS
Pharm TPI-ALV-202Hematology Acute LeukemiaOpen Active2020-06-26Tolero Pharmaceuticals TPI-ALV-202: A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax Combination Therapy
INST 0551CHematology Acute LeukemiaOpen Active2016-05-02INST 0551C, Project 4 Dynamic Analysis of Signaling Networks in Leukemia
Pharm INCB 18424-MA-GD-301Hematology Stem Cell TransplantOpen Active2019-01-29Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Pharm 63935937MDS3001Hematology OtherOpen Active2020-06-26Geron 63935937MDS3001: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
ECOG-ACRIN NHLBI-MDSHematology OtherOpen Active2020-05-18ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
SWOG S1803Hematology MyelomaOpen Active2019-11-14SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
SWOG S1608Hematology Lymphoma Non-HodgkinsOpen Active2020-08-05SWOG S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
SWOG S1826Hematology Lymphoma HodgkinsOpen Active2020-05-08SWOG S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-09Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
UNM 1709Ill DefinedOpen Active2019-05-30INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST 1306Ill DefinedOpen Active2015-01-01INST 1306: Whole Genome Sequencing of Human Cancer Tissues
Alliance A091802Skin Melanoma AdvancedOpen Active2019-12-06Alliance A091802: Phase II Randomized Trial of Avelumab Plus Cetuximab versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
EA2185Multiple SitesOpen Active2020-07-23EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
NRG-LU005Lung SCLC AdjuvantOpen Active2020-02-05NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
SWOG S1900CLung NSCLC AdvancedOpen Active2020-05-05SWOG S1900C: A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub-Study)
SWOG S1800ALung NSCLC AdvancedOpen Active2020-04-08SWOG S1800A: A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-14SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN EAY131-C1Solid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
SWOG S1801Skin Melanoma AdvancedOpen Active2020-04-03SWOG S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable State III-IV High Risk Melanoma
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2020-08-07ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131-Z1CSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2020-05-07ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-Z1LSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Alliance A151804SupportiveOpen Active2020-06-15Alliance A151804: Establishment of a National Biorepository to Advance Studies of Immune-related Adverse Events
Alliance A011401SupportiveOpen Active2016-10-02Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Pharm SGNS40-001Solid Tumors OtherOpen Active2019-12-18Seattle Genetics SGNS40-001: A Phase I, Open-label Dose Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies
Pharm R3767-ONC-1613Solid Tumors OtherOpen Active2017-12-15Regeneron Pharmaceuticals R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies
ECOG-ACRIN E1Q11SupportiveOpen Active2018-04-18ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-002SupportiveOpen Active2017-11-16NCI DCP-002: Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations
INST Johns Hopkins Hospital 1802SupportiveOpen Active2019-09-20INST Johns Hopkins Hospital 1802: A Multi-Center Randomized Control Trial of Perioperative Palliative Care Surrounding Surgery for Patients and Their Family Members
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
WFU WF-1801SupportiveOpen Active2019-09-27Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
WFU WF 97115SupportiveOpen Active2017-07-06WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer

Women's Cancer and Surgical Care

Trial #TypeStudy StatusStatus DateTitle
INST 96144Ill DefinedOpen Active2018-06-13INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives